Explore the words cloud of the GLADIATOR project. It provides you a very rough idea of what is the project "GLADIATOR" about.
The following table provides information about the project.
| Coordinator |
UNIVERSITY OF CYPRUS
Organization address contact info |
| Coordinator Country | Cyprus [CY] |
| Total cost | 6˙122˙255 € |
| EC max contribution | 5˙982˙255 € (98%) |
| Programme |
1. H2020-EU.1.2.1. (FET Open) |
| Code Call | H2020-FETOPEN-2018-2019-2020-01 |
| Funding Scheme | RIA |
| Starting year | 2019 |
| Duration (year-month-day) | from 2019-01-01 to 2022-12-31 |
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | UNIVERSITY OF CYPRUS | CY (NICOSIA) | coordinator | 953˙125.00 |
| 2 | FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. | DE (MUNCHEN) | participant | 1˙758˙103.00 |
| 3 | E.P.O.S. IASIS RESEARCH AND DEVELOPMENT LTD | CY (LEFKOSIA) | participant | 1˙111˙540.00 |
| 4 | OULUN YLIOPISTO | FI (OULU) | participant | 950˙535.00 |
| 5 | NORGES TEKNISK-NATURVITENSKAPELIGE UNIVERSITET NTNU | NO (TRONDHEIM) | participant | 787˙076.00 |
| 6 | WATERFORD INSTITUTE OF TECHNOLOGY | IE (Waterford) | participant | 421˙875.00 |
| 7 | OSAKA UNIVERSITY | JP (OSAKA) | participant | 0.00 |
Brain pathologies are highly complex disorders. Despite recent progress, their prognosis is grim, defining a high societal challenge. Bridging life sciences, bio-nanotechnology, engineering and ICT, GLADIATOR promises a vanguard and comprehensive theranostic (therapeuticdiagnostic) solution for brain malignancies. Through a multi-faceted breakthrough, GLADIATOR will provide, for the first time, a working prototype of a complete, autonomous and clinically applicable, nanonetwork-based, Molecular Communications system based on the conceptual framework of Externally Controllable Molecular Communications (ECMC). Using Glioblastoma Multiforme tumours, the most detrimental brain pathologies, as a proof-of-concept case, GLADIATOR will implement a platform of cell-based and electronic components. Implantable autologous organoids of engineered neural stem cells (iNSCs) will release rationally designed exosomal bio-nanomachines, delivering reprogramming (therapeutic) miRNAs and building nanonetworks. Interfering with the underlying biological environment, the nanonetworks will define a revolutionary intervention. A hybrid bio-electronic interface, consisting of coupled external and implantable devices, will enable communication channels with host-derived fluorescent bio-nanomachines via micro-optoelectronic sensors. The cellular, sub-cellular and electronic components will be integrated into a wireless ECMC network. This system will autonomously monitor the spatiotemporal tumour evolution and recurrence and generate, on demand, appropriate reprogramming interventions, by radiofrequency stimulation of iNSC renewal. A paradigm shift in Oncology Research is anticipated via the supra-discipline of “bio-nanomachine diagnostics”. GLADIATOR establishes a radical long-term vision leading to a drastic change in cancer therapy, also ushering the emergence of the ECMC field and transforming the burgeoning industry of Internet of Nano-bio-things, with high socioeconomic impact.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLADIATOR" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "GLADIATOR" are provided by the European Opendata Portal: CORDIS opendata.
Proactive FET Observatory for early trends, project building and social responsibility
Read MoreProduction of next generation modulators of pannexins and connexins as novel therapeutics in the treatment of inflammatory cardiovascular, hepatic and joint diseases.
Read More